23/07/2025 Roche's Itovebi regimen received approval in the EU for ER-positive, HER2-negative, advanced breast cancer with a PIK3CA...

🤝  Bristol Myers Squibb  is set to acquire  2seventy bio  in an all-cash transaction valued at approximately $286 million. After...